A clinical phase 1 trial with the TetMYB vaccine in combination with the PD-1 inhibitor tislelizumab was launched for CRC and ACC supported by a reported clinical response of MYB-NFIB-positive patients to the PD-1 inhibitor pembrolizumab[150,151]. This evidence concerns the gene MYB and colorectal carcinoma.